biostudies-literatureUnknown28(14)Marin D<h4>Purpose</h4>There is a considerable variability in the level of molecular responses achieved with imatinib therapy in patients with chronic myeloid leukemia (CML). These differences could result from variable therapy adherence.<h4>Methods</h4>Eighty-seven patients with chronic-phase CML treated with imatinib 400 mg/d for a median of 59.7 months (range, 25 to 104 months) who had achieved complete cytogenetic response had adherence monitored during a 3-month period by using a microelectronic monitoring device. Adherence was correlated with levels of molecular response. Other factors that could influence outcome were also analyzed.<h4>Results</h4>Median adherence rate was 98% (range, 24% to 104%). Twenty-three patients (26.4%) had adherence <or= 90%; in 12 of these patients (14%), adherenJournal of clinical oncology : official journal of the American Society of Clinical Oncology2381-8https://www.ebi.ac.uk/biostudies/studies/S-EPMC6366340biostudies-literatureAdherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.PMC6366340Kozlowski KMahon FXEliasson LReid ABua MLatham VGuallar CMolimard MSzydlo RDesai RPaliompeis CMilojkovic DKhorashad JSBazeos AForoni LGoldman JApperley JFRezvani KMarin Dde Lavallade HfalseAdherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.<h4>Purpose</h4>There is a considerable variability in the level of molecular responses achieved with imatinib therapy in patients with chronic myeloid leukemia (CML). These differences could result from variable therapy adherence.<h4>Methods</h4>Eighty-seven patients with chronic-phase CML treated with imatinib 400 mg/d for a median of 59.7 months (range, 25 to 104 months) who had achieved complete cytogenetic response had adherence monitored during a 3-month period by using a microelectronic monitoring device. Adherence was correlated with levels of molecular response. Other factors that could influence outcome were also analyzed.<h4>Results</h4>Median adherence rate was 98% (range, 24% to 104%). Twenty-three patients (26.4%) had adherence <or= 90%; in 12 of these patients (14%), adheren2010-01-01T00:00:00Z2010 May2025-06-01T12:39:51.136Z2025-06-01T12:39:51.136ZS-EPMC63663402038598610.1200/jco.2009.26.308710.1200/JCO.2009.26.3087